tbuckley/cabot-search huggingface dataset:
Effects of a gut pathobiont in a gnotobiotic mouse model of childhood undernutrition
Authors: Vitas E. Wagner, Neelendu Dey, Janaki Guruge, Ansel Hsiao, Philip P. Ahern, Nicholas P. Semenkovich, Laura V. Blanton, Jiye Cheng, Nicholas Griffin, Thaddeus S. Stappenbeck, Olga Ilkayeva, Christopher B. Newgard, William Petri, Rashidul Haque, Tahmeed Ahmed, Jeffrey I. Gordon
Journal: Science Translational Medicine (2016)

Pathobiont-associated cachexia in a gnotobiotic model of childhood undernutrition is determined by strain-level interactions within the gut microbiota.
Higher Dose of Opioids in the Emergency Department and Earlier Initiation of Oral Opioids after Hospitalization Are Associated with Shorter Length of Stay in Children with Sickle Cell Disease Treated for Acute Pain
Authors: Amanda M Brandow, Mark Nimmer, Timothy Simmons, T Charles Casper, Larry J Cook, J. Paul Scott, Julie A. Panepinto, David C. Brousseau
Journal: Blood (2015)
Cigarette Smoking Significantly Increases the Risk of Invasive Fungal Disease (IFD) in Acute Myeloid Leukemia (AML) Patients Undergoing Induction Chemotherapy,
Authors: Sudipto Mukherjee, Alex Zhengdong Fu, Mary Mansour, Matt Kalaycio, Edward A. Copelan, Anjali S. Advani, Ramon V. Tiu, Yogen Saunthararajah, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2011)
THU0268 Decreased Expression of MIR-130A and MIR-708 in Type-1 Classical Dendritic Cells of Sjögren's Syndrome Patients Indicates Their Dysregulation
Authors: M.R. Hillen, S.L. Blokland, E. Chouri, A.P. Lopes, A.A. Kruize, C.E. Hack, M. Rossato, T.R. Radstake, J.A. van Roon
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Primary Sjögren9s syndrome (pSS) is a systemic autoimmune disease characterized by lymphocytic infiltration of the salivary and lachrymal exocrine glands that leads to dryness of mouth and eyes. Type-1 classical dendritic cells (cDCs) are very potent antigen presenting cells known to induce strong T-cell proliferation and cytokine production. Despite the fact that especially cDC1s are candidate key players in the activation of local T and B-cells in pSS, they have rarely been studied in pSS. <h3>Objectives</h3> Considering the critical role of micro-RNAs (miRNAs) in regulation of gene expression, we investigated miRNA expression in isolated cDC1s of pSS patients. <h3>Methods</h3> Two independent cohorts (discovery and validation) were established including a total of 29 pSS patients. 17 healthy controls (HC) were included as control group. cD1c+CD19- cells were isolated from peripheral blood using MACS and we performed miRNA profiling of 758 miRNA targets using the OpenArray platform in the donors included in the discovery cohort. A selection of the miRNAs found to be differentially expressed in pSS versus HC was measured in the validation cohort. We performed pathway enrichment with the experimentally supported targets of the validated miRNAs. <h3>Results</h3> A total of 24 miRNAs were downregulated in pSS patients versus HC in the discovery cohort (all at least p&lt;0.05 and 2log expression difference). Of these, 16 targets were selected to be validated in validation cohort. Two miRNAs, miR-130a and miR-708, were significantly downregulated in pSS patients in both cohorts (p&lt;0.05). Pathway enrichment showed that the experimentally supported targets of these miRNAs are mainly involved in vesicle trafficking and a number of growth-factor signalling pathways (p&lt;0.05, FDR corrected), including epidermal growth factor (EGF) signalling and endocytosis. We are currently linking the miRNA expression data to RNAseq data and performing functional experiments with primary DCs to dissect the effects of miRNA dysregulation in these cells. <h3>Conclusions</h3> We here for the first time show differentially expressed miRNAs in an isolated immune cell subset of pSS patients. In addition, this is the first evidence for dysregulation of primary peripheral blood type-1 cDCs in pSS. Considering threimportant role of miRNAs in cell function, this suggests that targeting aberrant miRNA expression may provide tools to modulate cDC activity. <h3>Disclosure of Interest</h3> None declared
Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).
Authors: Olatoyosi Odenike, Emily Curran, Neil Iyengar, Leslie Popplewell, Mark Kirschbaum, Harry P Erba, Margaret Green, Xavier Poiré, Pamela Ihonor, Ernesto Diaz-Flores, Kevin Shannon, Ehab Atallah, James L Wade, Maria Perdekamp, Sreenivasa Nattam, Sachdev P. Thomas, Scott E. Smith, L. Austin Doyle, Elizabeth Shima Rich, Richard A. Larson, Wendy Stock
Journal: Blood (2009)
Promotion of Drugs for Off-label Uses
Authors: Jeanie Kim, Amy Kapczynski
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Induction of G1 Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: P53-Independent Upregulation of P21/WAF/CIP1.
Authors: Tobias Berg, Manfred Fliegauf, Jurij Pitako, Jan Burger, Mahmoud Abdelkarim, Yalin Guo, Martin S. Staege, Stefan Burdach, Michael Lübbert
Journal: Blood (2004)
FRI0036 Meta-Immunological Profiling of Patients with Behçet's Disease Reveals Novel Biomarkers of Disease Activity, Progression and Response To Therapy: Table 1.
Authors: V. Pucino, A. Vitale, O.M. Lucherini, R. Talarico, G. Marone, M. Galeazzi, G. Matarese, L. Cantarini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Behçet9s disease (BD) is a rare and poorly understood condition characterised by systemic inflammation. Current biomarkers are still largely insensitive and unable to predict disease progression and response to treatment in BD patients. <h3>Objectives</h3> The specific aims of this study were i) to explore serum levels of soluble CD40L (sCD40L), soluble intracellular-adhesion-molecule (sICAM-1), monocyte-chemoattractant-protein-1 (MCP-1), myeloperoxidase (MPO), leptin, resistin, osteoprotegerin (OPG), soluble-type 1 tumour-necrosis-factor-receptor (sTNFR), interleukin-6 (IL-6) and serum-amyloid-A (SAA); ii) to evaluate potential correlations between the putative circulating biomarkers with the demographic profile, disease activity, organ involvement, genetical background, and different therapeutic regimes. <h3>Methods</h3> 57 serum samples were collected from 27 BD patients and 35 healthy controls (HC) after written consent. Demographic and clinical data are summarized in Table 1. Adipocytokines were analyzed using the bead-based-analyte-detection-system. Data were acquired by flow-cytometry. SAA serum concentration was determined with a enzyme linked-immunosorbent assay (ELISA). We used ANOVA test to identify statistical differences. P&lt;0.05 was considered statistically significant. <h3>Results</h3> BD patients showed higher levels of circulating sTNFR (p=0.008), leptin (p=0.0011), sCD40L (&lt;0.0001), and IL-6 (p=0.0154) than HC while no difference was found in MCP-1, MPO, sICAM, and resistin serum levels. Patients HLA-B51- had higher sTNFR and sICAM-1 serum levels than HC (p=0.0034, p=0.0037, respectively), while sICAM levels were significantly higher in patients HLA-B51- than in patients HLAB51+ (p=0.0010) as well as leptin was significantly higher in both HLA-B51+ and HLA-B51- BD patients than in HC (p=0.0183, p=0.0303, respectively). Patients treated with biologic-agents showed significantly higher sTNFR and leptin serum levels when compared to DMARDs-treated-patients (p=0.0246,p=0.0023, respectively). Moreover, sTNFR was found higher in patients with inactive disease and in patients over 40 years than HC (p=0.0104, p=0.0329, respectively). <h3>Conclusions</h3> The identification of a specific meta-immunological profile associated with disease status and response to therapy may contribute to our understanding of the physiopathology processes underlying BD activity and damage as well as to provide useful tools for prognostic purposes and a personalized treatment approach. <h3>Disclosure of Interest</h3> None declared
SP0157 Delivering Technology Enabled Care Services in Primary Care
Authors: R. Chambers
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> there are many pilots of various types of technology enabled care in general practice settings in the UK. The challenge is to integrate such technology as a natural option for delivery of care in specific pathways or for particular patient groups, across and between healthcare settings. <h3>Project</h3> Adoption of technology enabled care in Staffordshire and beyond in general practice settings, and interacting with clinicians in acute care, mental health and community settings, and pharmacies. Modes of technology included locally evolved apps, Flo telehealth, skype and videoconsultations with encrypted mode, social media (eg Facebook); foci included patients with asthma, COPD, heart failure, hypertension, AF and other conditions. The presentation will capture challenges and how these have been overcome. <h3>Discussion</h3> How do we in the NHS match patients9 needs and preferences for technology enabled care? How do we prove to the commissioners of care and frontline practitioners that technology enabled care is worth doing? <h3>Disclosure of Interest</h3> None declared
SAT0620 Validation of The Dutch-Flemish Promis Fatigue Item Bank in Patients with Rheumatoid Arthritis
Authors: M.H. Crins, C.B. Terwee, R. Westhovens, D. van Schaardenburg, N. Smits, J. Joly, P. Verschueren, K. van der Elst, D. Cella, K.F. Cook, J. Dekker, M. Boers, L.D. Roorda
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In the assessment of patients with rheumatoid arthritis (RA) it is important to measure fatigue. The National Institutes of Health9s Patient-Reported Outcomes Measurement Information System (PROMIS) initiative developed an item bank for measuring fatigue. This item bank was translated into Dutch-Flemish language according to the FACIT methodology. <h3>Objectives</h3> The aim of current study was to validate the Dutch-Flemish translation of the PROMIS Fatigue item bank (DF-PROMIS-Fatigue) in Dutch and Flemish RA patients. This is the first validation study of the PROMIS Fatigue item bank in RA patients. <h3>Methods</h3> 2030 RA patients (1370 Dutch and 660 Flemish RA patients) completed a paper-and-pencil or web-based survey, including the full DF-PROMIS-Fatigue (95 items, 5-point Likert scale). One-factor confirmatory factor analysis assessed unidimensionality. Item response theory (IRT) models evaluated the item characteristics of the item bank, to facilitate future development of a computer adaptive test (CAT). A graded item response model (GRM) was fitted and construct validity was studied. Ordinal regression models evaluated Differential Item Functioning (DIF) for e.g. language (Dutch-Flemish vs. English and Dutch vs. Flemish), to analyse cross-cultural validity. <h3>Results</h3> The analyses support unidimensionality of the DF-PROMIS-Fatigue (CFI=0.996 and TLI=0.996). Only 45 out of 4465 (1%) item pairs were marked as possibly locally dependent. The data of the item bank fit the GRM, and showed good coverage across the fatigue continuum (threshold-parameters ranged from -3.8 to 5.8). The item bank showed good cross-cultural validity: none of the DF-PROMIS-Fatigue items showed DIF between Dutch and Flemish language. Furthermore, the item bank showed good reliability (Cronbach9s alpha=0.993). Analyses of construct validity are in progress and will be presented at the conference. <h3>Conclusions</h3> The results indicate that the items of the DF-PROMIS-Fatigue fit a GRM. The DF-PROMIS-Fatigue can be used to develop a CAT for measuring fatigue in Dutch and Flemish RA patients. <h3>Disclosure of Interest</h3> None declared
Gene Expression Profiling Predictive of Tipifarnib (ZARNESTRA®, R115777) Response in Patients with Newly Diagnosed Acute Myeloid Leukemia.
Authors: Mitch Raponi, Yi Zhang, Tim Jatkoe, Jack Yu, Grace Lee, Jeffrey E. Lancet, Judith E. Karp, Alain Thibault, Yixin Wang
Journal: Blood (2005)
Deletion of 13q14 Is Independent of CD38 Expression in Chronic Lymphocytic Leukemia (CLL).
Authors: Blanche H. Mavromatis, Bruce D. Cheson, Metin Ozdemirli, Dan-Paul Hartmann, Salah Abbasi, Emre Zafer, Nicole Zantek, Jessica Cooksey, Jeanne Meck
Journal: Blood (2004)
In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells
Authors: C Rodman, G Almeida-Porada, S K George, J Moon, S Soker, T Pardee, M Beaty, P Guida, S P Sajuthi, C D Langefeld, S J Walker, P F Wilson, C D Porada
Journal: Leukemia (2016)
SAT0131 A Look To The Wrong Diagnosis of Rheumatoid Arthritis
Authors: N. Palacio, D. Buitrago-Garcia, C. Castro, P. Santos-Moreno, L. Villarreal, G. Ballesteros, J. Bello, E. Castillo, R. Giraldo, D. Gomez, A. Aza, A. Lopez, A. Cardozo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There is a lack of expertise in rheumatoid arthritis (RA) diagnosis in primary level of Colombian medical centers, leading to misdiagnosis; many times osteoarthritis (OA) and another rheumatic diseases are misdiagnosed as RA which derives in wrong treatment for patients with clinical and health economics implications. <h3>Objectives</h3> The aim of this study was to describe demographic and clinical characteristics of a cohort of patients with misdiagnosis of RA in a specialized center in Colombia. <h3>Methods</h3> A descriptive, cross sectional study. Were included patients who were referred from primary care centers to a RA specialized center in a 48 month period with presumptive diagnosis of this disease. Each patient was evaluated to confirm or rule-out diagnosis of RA as follows: a rheumatologist fulfilled a complete medical record including all previous data; it was assessed rheumatoid factor and anti-citrullinated antibodies, and other laboratories depending on each case. Also were made x-rays of hands and feet, and in some cases of persistent doubt about the diagnosis was requested comparative MRI of hands or/and feet. Frequencies and percentages were calculated for the demographic and clinical characteristics of the cohort of patients in which the diagnosis of RA was ruled-out. <h3>Results</h3> In 5176 patients was found a wrong diagnosis of RA. Of these misdiagnosed patients, 4.385 (85%) were women, and 791 (15%) men, with an average age of 59 ± 13 years old. Between differential diagnosis which were found in this cohort of misdiagnosed patients: osteoarthritis in 2930 patients (56.6%), systemic lupus erythematosus (SLE) in 369 patients (7.1%), Sjögren syndrome in 237 patients (4.6%), spondyloarthropathies in 135 patients (2.6%), gout in 95 patients (1.8%), and in 28.3% of cases other diagnoses including all kinds of soft tissue rheumatism. <h3>Conclusions</h3> Almost half patients with presumptive RA diagnosis in primary care centers in Colombia are misdiagnosed. The most important cofounding diagnosis was osteoarthritis and many patients were receiving DMARDs for treatment. For this reason there is an urgent need of education strategies for primary care physicians and the implementation of centers of excellence in RA, in order to conduct a proper diagnose and avoid clinical and health economics consequences of misdiagnosis. <h3>Disclosure of Interest</h3> None declared
Lymphadenectomy for Treatment of Early-Stage Endometrial Cancer
Authors: Jonathan A. Frost, Katie E. Webster, Jo Morrison
Journal: JAMA Oncology (2016)

<h3>Clinical Question</h3> What is the association between lymphadenectomy and survival, disease recurrence, and surgical morbidity in women with presumed early-stage, low-grade endometrial carcinoma? <h3>Bottom Line</h3> The evidence from randomized clinical trials suggests that lymphadenectomy does not improve survival or decrease disease recurrence in women with early-stage, low-grade endometrial carcinoma. Furthermore lymphadenectomy is associated with an increase in both short- and long-term surgery-related systemic morbidity.
Frequent BRAF V600E Mutations Are Identified in CD207+ Cells in LCH Lesions, but BRAF Status does not Correlate with Clinical Presentation of Patients or Transcriptional Profiles of CD207+ Cells
Authors: Tricia L Peters, Tsz-Kwong Chris Man, Jeremy Price, Renelle George, Phaik Har Lim, Kenneth Matthew Heym, Miriam Merad, Kenneth L. McClain, Carl E Allen
Journal: Blood (2011)
Cyclin D1 Overexpression Increases Chemosensitivity Via Prolonged S-Phase and TRAIL Signal in Myeloma Cell.
Authors: Yoshiaki Kuroda, Akira Sakai, Naohiro Tsuyama, Yuta Katayama, Shoso Munemasa, Yoshiko Okikawa, Hideki Asaoku, Nanae Nakaju, Mami Mizuno, Takashi Nishizaka, Katsunari Ogawa, Hideo Tanaka, Akiro Kimura
Journal: Blood (2007)
Transcriptional Changes Induced by Imatinib and Nilotinib in the Chronic Myelogenous Leukemia (CML) Cell Line K562.
Authors: Frank Neumann, Daniela C. Bruennert, Anne-Marie Koch, Ingmar Bruns, Norbert Gattermann, Ralf Kronenwett, Rainer Haas
Journal: Blood (2007)
AB0426 Risk of Pneumocystis Carinii Pneumonia Infection in Patients with Systemic Lupus Erythematosus: A Nationwide Population Cohort Study: Table 1.
Authors: W.H. Wang, C.-C. Lai, Y.-S. Chang
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pneumocystis carinii pneumonia (PJP) infection often affects immunocompromised patients may cause severe morbidity and mortality. PJP may be preventable by prophylactic antibiotics in high risk patients. However, the epidemiology and risk factors for PJP in patients with systemic lupus erythematosus (SLE) are not full studied. <h3>Objectives</h3> This nationwide population-based study aimed to evaluate the risk of PJP in patients with systemic lupus erythematosus in Taiwan. <h3>Methods</h3> We identified 23,378 SLE patients from the National Health Insurance research database between 1997 and 2012 and compared the incidence rate (IR) of PJP infection with that of 93,512 age- and gender-matched non-SLE cohort. A Cox multivariable proportional hazards model was applied to evaluate the risk of PJP infection in the SLE cohort. Risk factors of PJP infection were also analyzed. <h3>Results</h3> The SLE cohort had a significantly higher IR of PJP infection (SLE IR=2.49, control IR=0.10, incidence rate ratio = 26.06, p&lt;0.001). Male (Hazard ratio [HR] = 2.05, p=0.039), end stage renal disease (HR=1.88, p=0.035), use of mycofenolate mofetil (HR=5.11, p&lt;0.001), intravenous steroid pulse therapy (HR=96.23, p&lt;0.001). <h3>Conclusions</h3> Higher risk of PJP infection was observed in SLE patients. Risk factors for PJP infection include male, end stage renal disease, use of mycofenolate mofetil, intravenous steroid pulse therapy and an oral daily steroid dose over 7.5mg. <h3>References</h3> Ratchaya Lertnawapan, Kitti Totemchokchyakarn, Kanokrat Nantiruj, Suchela Janwityanujit. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 2009;29:491–496. Michael M. Ward, Fiona Donald. Pneumocystis carinii pneumonia in patients with connective tissue diseases. Arthritis &amp; Rheumatism 1999;42:780–789. Chia-Tse Weng, Ming-Fei Liu, Meng-Yu Weng, et al. Pneumocystis jirovecii Pneumonia in Systemic Lupus Erythematosus From Southern Taiwan. J Clin Rheumatol. 2013;19:252–8. <h3>Disclosure of Interest</h3> None declared
Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study
Authors: Jean-Jacques Kiladjian, Tamás Masszi, Mark M. Jones, Brian Gadbaw, Jingjin Li, Dany Habr, Alessandro M. Vannucchi, Srdan Verstovsek
Journal: Blood (2015)
Auto-Immune Origin of B Cells from HCV-Associated Lymphoma
Authors: Marine Armand, Myriam Boudjoghra, Aliki Xochelli, Danielle Canioni, Magali Le Garff Tavernier, Monica Colombo, Pascaline Rabiega, Thierry Molina, Frederic Charlotte, Jean-Marie Michot, Claude Lesty, Fabrice Carrat, Manlio Ferrarini, Kostas Stamatopoulos, Caroline Besson, Olivier Hermine, Frederic Davi
Journal: Blood (2015)
Comparative Effectiveness of Fludarabine and Busulfan Versus Fludarabine and 400 cGy Total Body Irradiation Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation for AML/MDS
Authors: Moaath Mustafa Ali, Donna M Abounader, Lisa A. Rybicki, Melissa A Yurch, Jamie Starn, Christina Ferraro, Victoria Winslow, Betty K. Hamilton, Aaron T. Gerds, Hien Liu, Robert Dean, Brian T. Hill, Brad Pohlman, Steven Andresen, Rabi Hanna, Matt Kalaycio, Brian J. Bolwell, Navneet S. Majhail, Ronald Sobecks
Journal: Blood (2015)
Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case–Control Consortium (PanC4)
Authors: C. Pelucchi, V. Rosato, P.M. Bracci, D. Li, R.E. Neale, E. Lucenteforte, D. Serraino, K.E. Anderson, E. Fontham, E.A. Holly, M.M. Hassan, J. Polesel, C. Bosetti, L. Strayer, J. Su, P. Boffetta, E.J. Duell, C. La Vecchia
Journal: Annals of Oncology (2016)